Physician profile
Christopher Campos
NPI 1932762507
$1,238.62
in general payments reported to CMS, 2019-2025
15 companies · $554 in 2025
The $554 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $58.21 · 2024: $626 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,180.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $334.72 | 2024-2025 | Otezla, Repatha, Otezla |
| Gilead Sciences, INC. | $127.08 | 2024 | Vemlidy |
| Dexcom, INC. | $124.89 | 2024-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $105.80 | 2024-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $77.49 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $76.77 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $74.14 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $73.83 | 2024-2025 | Farxiga, Airsupra |
| Boston Scientific Corporation | $63.63 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $58.21 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.34 | 2024 | |
| Pfizer INC. | $21.87 | 2024 | |
| Esperion Therapeutics, INC. | $19.08 | 2025 | Nexletol |
| Seqirus USA INC | $17.99 | 2024 | Fluad |
| Endogastric Solutions, INC | $12.78 | 2024 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Campos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.